Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7,369
Recruiting: 3,967
Ph III recruiting: 537
Growth YoY: +9.4%
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3,405)

clinicaltrialsPublishedShowing 801–850 of 8,903 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05883644	Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)(SIERRA)	active not recruiting	Phase 3	111	AstraZenecaINDUSTRY	10	Sep 14, 2026	clinicaltrials
NCT06064097	A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)	recruiting	Phase 2	50	National Cancer Institute (NCI)NIH	5	Sep 14, 2026